EP Patent

EP1546138B1 — Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes

Assigned to Sandoz AS · Expires 2012-01-18 · 14y expired

What this patent protects

Raloxifene sulphuric acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed sulphuric acid addition salt…

USPTO Abstract

Raloxifene sulphuric acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed sulphuric acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene sulphuric acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation.

Drugs covered by this patent

Patent Metadata

Patent number
EP1546138B1
Jurisdiction
EP
Classification
Expires
2012-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.